CTLA4 and non-small cell lung carcinoma: In the treatment of metastatic NSCLC, a retrospective analysis has indicated that the combination of PD-1/PD-L1 immune checkpoint inhibitors with SBRT is significantly superior to the combination of CTLA-4 immune checkpoint inhibitors with SBRT.